Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score

Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score

Purpose. To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA) 4–10 ng/mL and develop a risk-stratification score model. Methods. The data of 345 patients who underwent transrectal ultrasound-guided prostate biopsy be...

Full description

Bibliographic Details
Main Authors:	Dong Fang, Da Ren, Chenglin Zhao, Xuesong Li, Wei Yu, Rui Wang, Huihui Wang, Chenguang Xi, Qun He, Xiaoying Wang, Zhongcheng Xin, Liqun Zhou
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2015/596797

Similar Items

Evaluation the contribution of PSA, DRE and TRUS in prostate biopsy
by: Hao-Shuoh Jeng, et al.
Published: (2004)

Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL
by: Katia R. Leite, et al.
Published: (2008-06-01)

The sufficiency of 6 core sextant prostate biopsy in patients with prostate specific antigen (PSA) values over 20 ng/mL
by: Cem Yücel, et al.
Published: (2018-06-01)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1
by: Lincoln GL Tan, et al.
Published: (2017-01-01)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
by: Alexandros Fiamegos, et al.

Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4–10 ng/mL
by: Po-Fan Hsieh, et al.
Published: (2018-08-01)

Serum and tissue monocyte differentiation in PSA value 4–10 ng/mL prostate cancer and benign prostatic hyperplasia
by: Yuanyuan Guo, et al.
Published: (2018-11-01)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
by: W. F. S. Busato, et al.
Published: (2015-04-01)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
by: Tsung-Hsin Chang, et al.
Published: (2020-10-01)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
by: Xin LIU, et al.
Published: (2015-11-01)

Comparison of Pathology and Prevalence of Prostate Cancer in Patients with PSA between 4-10 ng/ml
by: A Tabibi, et al.
Published: (2008-01-01)

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL
by: Yongqiang Zhou, et al.
Published: (2017-01-01)

PSA levels of 4.0 - 10 ng/ml and negative digital rectal examination: antibiotic therapy versus immediate prostate biopsy
by: Avraham Shtricker, et al.
Published: (2009-10-01)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml−1)
by: Jun Liu, et al.
Published: (2020-01-01)

Compare prostate cancer detection rate between 12- and 18-core prostate biopsy in patients with normal dre and serum psa level of 4.0-20.0 ng/ml
by: Bo-Ren Wang, et al.
Published: (2015-06-01)

Decision Tree Analysis for Prostate Cancer Prediction in Patients with Serum PSA 10 ng/ml or Less
by: Pantic Damjan N, et al.
Published: (2020-03-01)

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
by: Matteo Ferro, et al.
Published: (2013-01-01)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml-1
by: Cheng Wang, et al.
Published: (2021-01-01)

TRUS-MR Fusion Biopsy of the Prostate: Radiological and Histological Correlation
by: Michel Lavaerts, et al.
Published: (2016-11-01)

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml
by: Emerson P. Gregorio, et al.
Published: (2007-04-01)

Comparison of pain levels in fusion prostate biopsy and standard TRUS-Guided biopsy
by: Abdullah Demirtaş, et al.

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
by: Hugo A. Socrates Castro, et al.

Assessment of TRUS (with Colour Doppler) and MRI with TRUS Guided Biopsy in Prostatic Lesion Diagnosis – A Comparative Study
by: Mohammed Ahetasham, et al.
Published: (2019-07-01)

The role of the percentage free PSA in the diagnosis of prostate cancer in Blacks: Findings in indigenous West African men using TRUS guided biopsy
by: K.H. Tijani, et al.
Published: (2017-03-01)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
by: Niraj Kumar, et al.
Published: (2019-01-01)

Multiparametric MRI-Targeted TRUS Prostate Biopsies Using Visual Registration
by: Philippe Puech, et al.
Published: (2014-01-01)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml -1 and 10.1-20.0 ng ml -1 : a multicenter study
by: Yu-Rong Lin, et al.
Published: (2015-06-01)

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
by: Nadeem Shaida, et al.
Published: (2009-01-01)

Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.
by: Ruizhe Zhao, et al.
Published: (2014-01-01)

Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL
by: Sezgin Okcelik, et al.
Published: (2016-06-01)

Prostate Biopsy: What is the future of this old Procedure? The Multiparametric Magnetic Resonance Imaging MRI/TRUS fusion prostate biopsy
by: Luciano A. Favorito
Published: (2015-10-01)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
by: Rui Chen, et al.
Published: (2015-01-01)

Editorial Comment: Comparison of pain levels in fusion prostate biopsy and standard TRUS-Guided biopsy
by: Andre Luiz Lima Diniz

The role of MRI/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer
by: Andrea Benelli, et al.
Published: (2020-05-01)

Can multiparametric ultrasound improve cognitive MRI/TRUS fusion prostate biopsy
by: Pietro Pepe, et al.
Published: (2020-06-01)

Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
by: Gokhan Koc, MD, et al.
Published: (2017-01-01)

In biopsy-naïve patients who underwent MRI-TRUS fusion biopsy, is the associated standard biopsy an additional value?
by: E. Checcucci, et al.
Published: (2020-07-01)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
by: I. Vukovic, et al.

Can we improve the detection rate of prostate cancer using standard 12‐core TRUS‐guided prostate biopsy? Focused on the location of prostate biopsy
by: Sangjun Yoo, et al.
Published: (2020-06-01)

Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/ml undergoing radical cystoprostatectomy for bladder cancer in iranian men
by: S.Y. Hosseini, et al.
Published: (2007-04-01)

Cannot write session to /tmp/vufind_sessions/sess_gupinsjpmn9q52nq10bb5i0m87